Table 5.

Univariate/multivariate analyses of factors associated with prognosis in the p-DCS group

		Univariate analysis				Multivariate analysis
Variable		No. of patients	HR	95% CI	P value	HR	95% CI	P value
Age (years)	≥70	15	1.470	(0.607–3.560)	0.393
	<70	24
Gender	Male	32	0.409	(0.156–1.075)	0.070	0.281	(0.093–0.846)	0.024
	Female	7
ECOG performance status	≥1	2	0.894	(0.119–6.698)	0.913
	0	37
Borrmann macroscopic type	Non-type 4	38	0.452	(0.059–3.439)	0.443
	Type 4	1
Differentiation	Diffuse	18	0.758	(0.310–1.854)	0.543
	Intestinal	21
PAN metastasis	(+)	16	1.869	(0.539–4.854)	0.201
	(−)	23
Hepatic metastasis	(+)	9	2.508	(0.993–6.333)	0.052	1.718	(0.530–5.570)	0.367
	(−)	30
RECIST	SD, PD	10	1.769	(0.705–4.439)	0.225
	CR, PR	29
Histological evaluation	0, 1a, 1b	17	2.84	(1.152–7.000)	0.023	1.938	(0.612–6.129)	0.260
	2, 3	22
CD42b expression	≥10%	24	3.644	(1.213–10.95)	0.021	4.406	(1.325–14.65)	0.016
	<10%	15
Podoplanin expression	(+)	28	1.411	(0.512–3.889)	0.505
	(−)	11
SNAIL expression	(+)	30	1.736	(0.664–4.539)	0.261
	(−)	9
FOXP3 expression	(+)	7	1.272	(0.369–4.386)	0.703
	(−)	32

CI confidence interval, CR complete response, ECOG Eastern Cooperative Oncology Group, FOXP3 forkhead box P3, HR hazard ratio, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable diseases